Evidence map›Paper›PMID 21127875›Full record

ArticleRheumatology international2012

Nine cases of Alkaptonuria in one family in southern Jordan.

Mohammed Al-Sbou, Nesrin Mwafi

Abstract read
PubMed Publisher
In one paragraph

Article in Rheumatology international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Alkaptonuria.Nature reviews. Disease primers · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Alkaptonuria: Current Perspectives.The application of clinical genetics · 2020
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. An update on molecular genetics of Alkaptonuria (AKU).Journal of inherited metabolic disease · 2011
    Article
  13. Article
  14. Alkaptonuria, more than just a mere disease.Journal of neurosciences in rural practice
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Mohammed Al-SbouDepartment of Pharmacology, Alkptonuria Research Office, Faculty of Medicine, Mutah University, P.O. Box 7, Mutah, Karak 61710, Jordan. malsbou@mutah.edu.jo
Nesrin Mwafi
Mutah University · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alkaptonuria is a rare autosomal recessive metabolic disorder characterized by a deficiency of homogentisate 1,2-dioxygenase (HGO) in the liver. This results in excretion of large quantities of homogentisic acid (HGA) (also called alkapton) in the urine and a slowly progressive deposition of homogentisic acid and its oxidative product in connective tissues. Clinical characteristic features of alkaptonuria are darkening of urine, bluish-dark pigmentation of connective tissues (ochronosis) and arthritis of large joints and spine. Cardiovascular and genitourinary systems may also be affected. In this report, we present the initial results of screening family members with history of alkaptonuria in southern region of Jordan. We present 9 cases of alkaptonuria (two males and seven females) in one Jordanian family. The history, signs and symptoms, diagnostic techniques and treatment options of alkaptonuria are reviewed in this article.

Indexed as

Family HealthPedigreeAdolescentAdultAlkaptonuriaFemaleHeterozygoteHumansJordanMaleMiddle AgedYoung Adult

Identifiers

PMID21127875
OpenAlexW2048774957

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.